CAR-T cell therapy in hematological malignancies: current opportunities and challenges
X Zhang, L Zhu, H Zhang, S Chen, Y Xiao - Frontiers in immunology, 2022 - frontiersin.org
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …
treatment, and it has achieved unprecedented success in hematological malignancies …
How I treat refractory CRS and ICANS after CAR T-cell therapy
MD Jain, M Smith, NN Shah - … Journal of the American Society of …, 2023 - ashpublications.org
The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly
because of the expanding indications for standard-of-care treatment and the development of …
because of the expanding indications for standard-of-care treatment and the development of …
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
A Mackensen, F Müller, D Mougiakakos, S Böltz… - Nature medicine, 2022 - nature.com
Systemic lupus erythematosus (SLE) is a life-threatening autoimmune disease characterized
by adaptive immune system activation, formation of double-stranded DNA autoantibodies …
by adaptive immune system activation, formation of double-stranded DNA autoantibodies …
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany
CD19-directed chimeric antigen receptor (CAR) T cells have evolved as a new standard-of-
care (SOC) treatment in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) …
care (SOC) treatment in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) …
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Hematological toxicity is the most common adverse event after chimeric antigen receptor
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …
How I treat cytopenias after CAR T-cell therapy
Increasing use of chimeric antigen receptor T-cell therapy (CAR-T) has unveiled diverse
toxicities warranting specific recognition and management. Cytopenias occurring after CAR …
toxicities warranting specific recognition and management. Cytopenias occurring after CAR …
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
K Rejeski, A Perez, G Iacoboni, V Blumenberg… - Science …, 2023 - science.org
Prolonged cytopenias after chimeric antigen receptor (CAR) T cell therapy are a significant
clinical problem and the underlying pathophysiology remains poorly understood. Here, we …
clinical problem and the underlying pathophysiology remains poorly understood. Here, we …
[HTML][HTML] The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
K Rejeski, A Perez, G Iacoboni, O Penack… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) represents a
promising treatment modality for an increasing number of B-cell malignancies. However …
promising treatment modality for an increasing number of B-cell malignancies. However …
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European …
T-cell redirecting bispecific antibodies (BsAbs) and chimeric antigen receptor T cells (CAR T
cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine …
cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine …
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma
C Roddie, L Neill, W Osborne, S Iyengar… - Blood …, 2023 - ashpublications.org
The impact of bridging therapy (BT) on CD19-directed chimeric antigen receptor T-cell
(CD19CAR-T) outcomes in large B-cell lymphoma (LBCL) is poorly characterized. Current …
(CD19CAR-T) outcomes in large B-cell lymphoma (LBCL) is poorly characterized. Current …